Vimpat
Product Images NDC 70166-617

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Vimpat (NDC 70166-617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lohxa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display 20 Units (Lacosamide 11)

Label for Vimpat (lacosamide) oral solution, 100 mg per 10 mL, in a package containing 20 units of 10 mL each. The label includes the NDC 70166-617-10, indicates Rx only, and notes storage at controlled room temperature (20 to 25 °C). It warns phenylketonurics about the phenylalanine content. The product is repackaged by Lohxa, Worcester, MA, U.S.A., with the Lohxa website shown.*

FDA Label Image

Chemical Structure (Vimpat 01)

Chemical structure of the active ingredient in Vimpat, as shown in the image. The diagram illustrates the molecular composition with carbon, hydrogen, nitrogen, and oxygen atoms arranged in a specific bonding pattern.*

FDA Label Image

Figure 1 (Vimpat 02)

A bar graph showing the median percent reduction in seizure frequency per 28 days from baseline to the maintenance phase by dose in three studies for Vimpat. The graph compares seizure reduction percentages for placebo and various Vimpat doses, indicating higher reductions with Vimpat across studies, with statistical significance marked versus placebo.*

FDA Label Image

Figure 2 (Vimpat 03)

A line graph titled 'Proportion of Patients by Responder Rate for VIMPAT and Placebo Groups in Studies 2, 3, and 4.' It displays responder rates (equal to or greater) on the vertical axis from -100% (worsening) to 100% (improvement) versus the percent of patients on the horizontal axis from 100% to 0%. The graph compares placebo (solid line) and three Vimpat dosages: 200 mg/day (dashed line), 400 mg/day (long dashed line), and 600 mg/day (dash-dot line), showing patient distribution across responder rates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.